BioNTech SE (BNTX)
BNTX Stock Price Chart
Explore BioNTech SE interactive price chart. Choose custom timeframes to analyze BNTX price movements and trends.
BNTX Company Profile
Discover essential business fundamentals and corporate details for BioNTech SE (BNTX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
10 Oct 2019
Employees
6.77K
Website
https://www.biontech.deCEO
Ugur Sahin
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
BNTX Financial Timeline
Browse a chronological timeline of BioNTech SE corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 3 Nov 2025
EPS estimate is $0.62, while revenue estimate is $1.19B.
Earnings released on 4 Aug 2025
EPS came in at -$1.82 falling short of the estimated -$1.31 by -38.93%, while revenue for the quarter reached $307.08M , beating expectations by +83.14%.
Earnings released on 5 May 2025
EPS came in at -$1.82 surpassing the estimated -$2.77 by +34.30%, while revenue for the quarter reached $200.39M , beating expectations by +35.77%.
Earnings released on 10 Mar 2025
EPS came in at $1.15 surpassing the estimated $0.61 by +88.52%, while revenue for the quarter reached $1.23B , beating expectations by +609.60%.
Earnings released on 4 Nov 2024
EPS came in at $0.87 surpassing the estimated -$1.67 by +151.92%, while revenue for the quarter reached $1.39B , missing expectations by -3.17%.
Earnings released on 5 Aug 2024
EPS came in at -$3.62 falling short of the estimated -$2.16 by -67.59%, while revenue for the quarter reached $138.38M , missing expectations by -26.00%.
Earnings released on 6 May 2024
EPS came in at -$1.42 falling short of the estimated -$0.82 by -73.17%, while revenue for the quarter reached $201.53M , beating expectations by +9.62%.
Earnings released on 20 Mar 2024
EPS came in at $2.06 falling short of the estimated $2.62 by -21.37%, while revenue for the quarter reached $1.63B , missing expectations by -24.45%.
Earnings released on 6 Nov 2023
EPS came in at $0.72 surpassing the estimated -$0.11 by +770.41%, while revenue for the quarter reached $944.40M , missing expectations by -62.08%.
Earnings released on 7 Aug 2023
EPS came in at -$0.86 falling short of the estimated -$0.75 by -14.67%, while revenue for the quarter reached $182.95M , missing expectations by -77.50%.
Earnings released on 8 May 2023
EPS came in at $2.24 surpassing the estimated $0.15 by +1.37K%, while revenue for the quarter reached $1.39B , missing expectations by -19.97%.
Earnings released on 27 Mar 2023
EPS came in at $10.07 surpassing the estimated $8.69 by +15.88%, while revenue for the quarter reached $4.61B , missing expectations by -0.21%.
Earnings released on 7 Nov 2022
EPS came in at $7.13 surpassing the estimated $4.61 by +54.66%, while revenue for the quarter reached $3.38B , beating expectations by +67.02%.
Earnings released on 8 Aug 2022
EPS came in at $6.62 falling short of the estimated $7.26 by -8.82%, while revenue for the quarter reached $3.34B , missing expectations by -17.86%.
Earnings released on 9 May 2022
EPS came in at $14.87 surpassing the estimated $9.65 by +54.09%, while revenue for the quarter reached $7.05B , beating expectations by +46.94%.
Dividend declared on 27 Apr 2022
A dividend of $2.11 per share was announced, adjusted to $2.11. The dividend was paid on 17 Jun 2022.
Earnings released on 30 Mar 2022
EPS came in at $13.47 surpassing the estimated $8.23 by +63.67%, while revenue for the quarter reached $6.27B , beating expectations by +40.83%.
Earnings released on 9 Nov 2021
EPS came in at $14.16 surpassing the estimated $12.62 by +12.20%, while revenue for the quarter reached $7.07B , beating expectations by +24.40%.
Earnings released on 9 Aug 2021
EPS came in at $12.65 surpassing the estimated $8.91 by +41.98%, while revenue for the quarter reached $6.30B , beating expectations by +93.07%.
Earnings released on 10 May 2021
EPS came in at $5.32 surpassing the estimated $3.74 by +42.25%, while revenue for the quarter reached $2.41B , beating expectations by +23.05%.
Earnings released on 30 Mar 2021
EPS came in at $1.85 surpassing the estimated -$0.18 by +1.15K%, while revenue for the quarter reached $423.64M .
Earnings released on 10 Nov 2020
EPS came in at -$1.03 falling short of the estimated -$0.46 by -123.91%, while revenue for the quarter reached $79.20M , beating expectations by +25.37%.
BNTX Stock Performance
Access detailed BNTX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.